vorinostat has been researched along with Cancer of Gastrointestinal Tract in 6 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The most common drug-related adverse events were anorexia, nausea, fatigue, and hyperglycemia." | 2.78 | Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. ( Chin, K; Doi, T; Hamaguchi, T; Hatake, K; Mehta, A; Noguchi, K; Ohtsu, A; Otsuki, T; Shirao, K, 2013) |
| "Vorinostat was administered orally once daily, 3 h before each radiotherapy fraction, at the following dose levels: 100 mg (n=1), 200 mg (n=4), 300 mg (n=6), and 400 mg (n=6)." | 2.75 | Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. ( Abrahamsen, TW; Dueland, S; Flatmark, K; Folkvord, S; Hole, KH; Johansen, M; Ree, AH; Seierstad, T, 2010) |
| " In this Pelvic Radiation and Vorinostat (PRAVO) study, we investigated mechanisms of adverse effects in response to the histone deacetylase (HDAC) inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) when administered as a potential radiosensitiser." | 1.46 | Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy. ( Andersen, SN; Barua, IS; Dueland, S; Flatmark, K; Kalanxhi, E; Lindvall, JM; Pettersen, SJ; Redalen, KR; Ree, AH; Risberg, K; Waagene, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, S | 1 |
| Chen, Z | 1 |
| Wang, L | 1 |
| Peng, D | 1 |
| Belkhiri, A | 1 |
| Lockhart, AC | 1 |
| El-Rifai, W | 1 |
| Kalanxhi, E | 1 |
| Risberg, K | 1 |
| Barua, IS | 1 |
| Dueland, S | 2 |
| Waagene, S | 1 |
| Andersen, SN | 1 |
| Pettersen, SJ | 1 |
| Lindvall, JM | 1 |
| Redalen, KR | 1 |
| Flatmark, K | 2 |
| Ree, AH | 2 |
| Folkvord, S | 1 |
| Hole, KH | 1 |
| Seierstad, T | 1 |
| Johansen, M | 1 |
| Abrahamsen, TW | 1 |
| Park, MA | 2 |
| Mitchell, C | 1 |
| Zhang, G | 1 |
| Yacoub, A | 2 |
| Allegood, J | 1 |
| Häussinger, D | 2 |
| Reinehr, R | 2 |
| Larner, A | 1 |
| Spiegel, S | 1 |
| Fisher, PB | 1 |
| Voelkel-Johnson, C | 2 |
| Ogretmen, B | 2 |
| Grant, S | 2 |
| Dent, P | 2 |
| Doi, T | 1 |
| Hamaguchi, T | 1 |
| Shirao, K | 1 |
| Chin, K | 1 |
| Hatake, K | 1 |
| Noguchi, K | 1 |
| Otsuki, T | 1 |
| Mehta, A | 1 |
| Ohtsu, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.[NCT00455351] | Phase 1 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| MK0683 Phase1 Clinical Study - Solid Tumor -[NCT00373490] | Phase 1 | 16 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 ｈours. It is obtained from AUC (0 - 24) plus AUC (24 - ∞) (NCT00373490)
Timeframe: Day 21 (400 mg)
| Intervention | μM·hr (Geometric Mean) |
|---|---|
| Vorinostat 400 mg | 8.3 |
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to extrapolated infinite time (o- ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). At 600 mg, t=12 hours and at 400 mg, t=24 hours. (NCT00373490)
Timeframe: Day 1 (600 mg and 400 mg)
| Intervention | μM·hr (Geometric Mean) |
|---|---|
| Vorinostat 600 mg | 3.94 |
| Vorinostat 400 mg | 7.75 |
Area Under Curve (AUC(0-infinity))=Area under the plasma concentration versus time curve (AUC) from time zero to 24 ｈours. It is obtained from AUC (0 - 12) plus AUC (12 - ∞) (NCT00373490)
Timeframe: Day 3 (600 mg)
| Intervention | μM·hr (Geometric Mean) |
|---|---|
| Vorinostat 600 mg | 4.15 |
(NCT00373490)
Timeframe: Day 1 (600 mg and 400 mg)
| Intervention | μM (Geometric Mean) |
|---|---|
| Vorinostat 600 mg | 1.17 |
| Vorinostat 400 mg | 1.62 |
(NCT00373490)
Timeframe: Day 21 (400 mg)
| Intervention | μM (Geometric Mean) |
|---|---|
| Vorinostat 400 mg | 2.04 |
(NCT00373490)
Timeframe: Day 3 (600 mg)
| Intervention | μM (Geometric Mean) |
|---|---|
| Vorinostat 600 mg | 1.32 |
Dose Limiting Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment (NCT00373490)
Timeframe: 21 Days (first cycle)
| Intervention | Participants (Number) |
|---|---|
| Vorinostat 600 mg | 0 |
| Vorinostat 400 mg | 2 |
2 trials available for vorinostat and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Topics: Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, D | 2010 |
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
Topics: Aged; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gas | 2013 |
4 other studies available for vorinostat and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
A Combination of SAHA and Quinacrine Is Effective in Inducing Cancer Cell Death in Upper Gastrointestinal Cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; | 2018 |
Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Line; Clinical | 2017 |
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcium; Carboxylic Este | 2010 |
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Topics: Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; | 2010 |